VIGL - Vigil Neuroscience reports interim Phase 2 data for ALSP drug candidate
2023-11-16 17:42:36 ET
More on Vigil Neuroscience
- Vigil Neuroscience: Interesting Early Data, Wait For Phase 2
- Vigil Neuroscience GAAP EPS of -$0.53 beats by $0.03
- Vigil Neuro rises as dosing starts in Phase 1 trial for Alzheimer’s drug
- Seeking Alpha’s Quant Rating on Vigil Neuroscience
- Historical earnings data for Vigil Neuroscience
For further details see:
Vigil Neuroscience reports interim Phase 2 data for ALSP drug candidate